|Bid||4.0000 x 3000|
|Ask||4.1000 x 900|
|Day's Range||3.9500 - 4.4400|
|52 Week Range||1.5600 - 5.0000|
|Beta (3Y Monthly)||2.55|
|PE Ratio (TTM)||4.26|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
- Phase 1 Trial of Sleeping Beauty-TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 –- Third-generation Sleeping Beauty.
BOSTON, Feb. 25, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Tuesday, March 5,.
BOSTON, Feb. 21, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that Chief Executive Officer Laurence Cooper, M.D., Ph.D, is scheduled to present and participate.
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Laurence James Cooper has been the CEORead More...
Ziopharm Oncology, Inc. (ZIOP) today announced that it rapidly completed enrollment and treated a total of 36 patients in less than six months in a substudy (Clinicaltrials.gov NCT03679754) to expand a Phase 1 trial evaluating its Controlled IL-12 platform as a monotherapy for the treatment of recurrent glioblastoma (rGBM). The trial was over enrolled with eleven more patients than the target goal of 25, which the Company attributes to enthusiasm stemming from the trial’s encouraging survival and tumor biopsy data. Ziopharm is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as a drug to control the production of interleukin 12 (IL-12).
The market for cell therapies of all kinds is exploding in size. Orgenesis Inc (ORGS) is making a name for itself as a top-notch provider of manufacturing to cell therapy drug developers. The company's revenue is growing consistently, and they recently achieved a key milestone under a 2018 investment agreement from a leading healthcare investment groups in the U.S., Great Point Partners.
HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold ...
The new license agreement helped pave the way for us to raise $50 million in a private placement from existing investors, secure a clinical collaboration with Regeneron Pharmaceuticals for Controlled IL-12 and announce a joint venture with committed funding of up to $35 million to bring our Sleeping Beauty platform for CD19-specific CAR-T to China. As we begin 2019, Ziopharm is already better.
Ziopharm Oncology, Inc. (ZIOP) today responded to the recent decline in the Company’s stock price, which accelerated greatly on December 26, 2018, the same day that the broader market and all indexes were up significantly. To the extent this price drop may have been attributable to any market confusion over exclusivity to its assets, the Company wishes to make clear the terms of its exclusivity to such assets. “Our stock price is significantly down of late, and we want to assure the market that our business fundamentals are unchanged and we are optimistic about Ziopharm’s future especially in light of the recent announcements we made with regards to our restructured relationship with Intrexon, the securing of a clean and longer-term balance sheet, and two partnerships with Regeneron and Eden BioCell.
CORAL GABLES, FL/ ACCESSWIRE / December 27,2018 / As the new year is rapidly approaching, companies in the healthcare sector are working tirelessly to create and implement nuanced methods for treating patients with a myriad of diseases and ailments. From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Allscripts Healthcare Solutions Inc (MDRX), ZIOPHARM Oncology Inc (ZIOP), and Sesen Bio Inc (SESN) are 4 healthcare stocks worth paying attention to before the end of the year. Premier Health Group (PHGRF) (PHGI), a company dominating the telehealth sector of the healthcare industry, has enjoyed a strong month of bullish trading, with Company shares soaring well above the 30% mark in a 30-day period.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
Ziopharm Oncology (ZIOP) needs investors to pay close attention to the stock based on moves in the options market lately.
BOSTON, Dec. 21, 2018 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 37th Annual J.P..
-- Joint venture to operate as Eden BioCell -- -- TriArm Therapeutics, a Panacea Venture Healthcare company, to fund Eden BioCell with up to $35M -- -- Ziopharm to license.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 13) Kezar Life Sciences Inc (NASDAQ: KZR ) Down In The Dumps ...
BOSTON, Dec. 13, 2018 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., has been promoted to President effective immediately. Dr. Mauney, who.
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.
Ziopharm Oncology, Inc. (ZIOP) today provided an update on its Controlled IL-12 platform following a presentation of positive data from its phase 1 clinical trial in recurrent glioblastoma (rGBM) at the Society for Neuro-Oncology (SNO) annual meeting in New Orleans. Ziopharm is developing Controlled IL-12, or Ad-RTS-hIL-12 plus veledimex, a gene therapy that controls the expression of interleukin 12 (IL-12), for the treatment of rGBM as both a monotherapy and in combination with immune checkpoint inhibitors.